Overexpression of CREG attenuates atherosclerotic endothelium apoptosis via VEGF/PI3K/AKT pathway

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 543-551

  Wang, Na ^a   Han, Yaling ^a   Tao, Jie ^a   Huang, Mingfang ^b   You, Yang ^a   Zhang, Huimin ^a   Liu, Shaowei ^a   Zhang, Xiaolin ^a   Yan, Chenghui ^a  

^a Shenyang Northern Hospital   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Atherogenesis; Cellular repressor of E1A stimulated genes (CREG); Vascular endothelium

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOVIRUS VECTOR; APOLIPOPROTEIN E; CASPASE 3; CELLULAR REPRESSOR OF E1A STIMULATED PROTEIN; ETOPOSIDE; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAUROSPORINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; WORTMANNIN;

ANIMAL TISSUE; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROTECTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LOSS OF FUNCTION MUTATION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; ETOPOSIDE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053286380     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.002     Document Type: Article

References (34)

1. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
2. Borradaile N.M., Pickering J.G. Polyploidy impairs human aortic endothelial cell function and is prevented by nicotinamide phosphoribosyltransferase. Am J Physiol Cell Physiol 2010, 298:C66-C74.
3. Correale M., Brunetti N.D., De Gennaro L., Di Biase M. Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc Hematol Agents Med Chem 2008, 6:272-277.
4. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:266-274.
5. Vanhoutte P.M. Hypercholesterolaemia, atherosclerosis and release of endothelium-derived relaxing factor by aggregating platelets. Eur Heart J 1991, 12(Suppl. E):25-32.
6. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997, 18(Suppl. E):E19-E29.
7. Feletou M., Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006, 291:H985-H1002.
8. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009, 73:595-601.
9. Vanhoutte P.M., Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989, 80:1-9.
10. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997, 811:60-67. discussion 7-9.
11. Vanhoutte P.M., Shimokawa H., Tang E.H., Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009, 196:193-222.
12. Ashton S.V., Whitley G.S., Dash P.R., et al. Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblasts through Fas/FasL interactions. Arterioscler Thromb Vasc Biol 2005, 25:102-108.
13. Jagielska J., Salguero G., Schieffer B., Bavendiek U. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?. Atherosclerosis 2009, 206:390-396.
14. Wu S., Ko Y.S., Teng M.S., et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 2002, 34:1595-1607.
15. Herr I., Gassler N., Friess H., Buchler M.W. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis 2007, 12:271-291.
16. Veal E., Groisman R., Eisenstein M., Gill G. The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells. Oncogene 2000, 19:2120-2128.
17. Han Y., Deng J., Guo L., et al. CREG promotes a mature smooth muscle cell phenotype and reduces neointimal formation in balloon-injured rat carotid artery. Cardiovasc Res 2008, 78:597-604.
18. Han Y., Wu G., Deng J., et al. Cellular repressor of E1A-stimulated genes inhibits human vascular smooth muscle cell apoptosis via blocking P38/JNK MAP kinase activation. J Mol Cell Cardiol 2010, 48:1225-1235.
19. Deng J., Han Y., Yan C., et al. Overexpressing cellular repressor of E1A-stimulated genes protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt. Apoptosis 2010, 15:463-473.
20. Riou S., Mees B., Esposito B., et al. High pressure promotes monocyte adhesion to the vascular wall. Circ Res 2007, 100:1226-1233.
21. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756.
22. Ohashi H., Takagi H., Oh H., et al. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 2004, 94:785-793.
23. Chang F., Lee J.T., Navolanic P.M., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603.
24. Berk B.C., Abe J.I., Min W., Surapisitchat J., Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 2001, 947:93-109. discussion 11.
25. Asada S., Takahashi T., Isodono K., et al. Downregulation of Dicer expression by serum withdrawal sensitizes human endothelial cells to apoptosis. Am J Physiol Heart Circ Physiol 2008, 295:H2512-H2521.
26. Xu L., Liu J.M., Chen L.Y. CREG. a new regulator of ERK1/2 in cardiac hypertrophy. J Hypertens 2004, 22:1579-1587.
27. Connolly D.T. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991, 47:219-223.
28. Coultas L., Chawengsaksophak K., Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005, 438:937-945.
29. Huang Y., Hua K., Zhou X., et al. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res 2008, 18:780-791.
30. Yang G., Han Y., Tian X., Tao J., Sun M., Kang J., Yan C. Pattern of expression of the CREG gene and CREG protein in the mouse embryo. Mol Biol Rep 2011, 38(3):2133-2140.
31. Han Y., Luan B., Sun M., et al. Glycosylation-independent binding to extracellular domains 11-13 of mannose-6-phosphate/insulin-like growth factor-2 receptor mediates the effects of soluble CREG on the phenotypic modulation of vascular smooth muscle cells. J Mol Cell Cardiol 2011, 50:723-730.
32. Ishii Y., Langberg J., Rosborough K., Mikawa T. Endothelial cell lineages of the heart. Cell Tissue Res 2009, 335:67-73.
33. Clarke M., Bennett M., Littlewood T. Cell death in the cardiovascular system. Heart 2007, 93:659-664.
34. Frey R.S., Ushio-Fukai M., Malik A.B. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009, 11:791-810.